

New results suggest that DiviTum[®] reflects response to palbociclib

New DiviTum[®] results will be presented at the San Antonio Breast Cancer Symposium, 4-8 December. The data originates from a collaboration with the Prato Hospital, Italy and Baylor College, Houston, US and supports DiviTum[®] as a biomarker for evaluating effects of a new targeted drug in breast cancer.

Palbociclib is a successful targeted drug from Pfizer for patients with metastatic breast cancer. The drug was launched in 2015 and is currently selling for >\$2 billion per year. Currently, no biomarkers are used for prognosis and monitoring of patients treated with Palbociclib.

The study data demonstrate that thymidine kinase can be an early marker of growth inhibition in response to palbociclib.

"This study provides more understanding and knowledge of the effect of treatment with palbociclib on a cellular level and evidence that the efficacy of palbociclib is reflected with DiviTum[®] and is directly related to treatment effect", says Dr Luca Malorni, Prato Hospital, Italy.

"In this pre-clinical trial, we are able to repeat the same pattern we've seen in clinical trials. This strengthens the hypothesis that DiviTum[®] is a valuable tool as a pharmacodynamic marker of CDK 4/6 inhibition. Our aim is to contribute to more personalized cancer treatment for the best possible outcome for the patient," says Anders Rylander, CEO, Biovica International AB.

Reference:

https://www.abstracts2view.com/sabcs18/view.php?nu=SABCS18L_668

Contact

Anders Rylander, CEO Biovica.

Phone: +46 (0)18 444 48 35,

E-mail: anders.rylander@biovica.com

I händelse av motsägelser eller skiljaktigheter mellan det engelska pressmeddelandet och denna svenska översättning av det engelska pressmeddelandet ska den engelska texten ges företräde.

Biovica – Best Possible Treatment from Day One.

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company's DiviTum[®] assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.

Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum[®] is CE labelled and MPA registered.

Webb www.biovica.com

Contact info@biovica.com